The kinase inhibitor dabrafenib halts progression of cerebral cavernous malformations in a BRAF-independent manner.

Dabrafenib, a clinically approved BRAF inhibitor, halts cavernoma progression and reduces lesion burden in mouse models of cerebral cavernous malformations independently of BRAF inhibition.

• Why it matters: Cerebral cavernous malformations often require surgical removal, but multiple lesions in patients highlight the need for pharmacological treatments. Understanding how existing drugs can target CCM pathology could improve patient care.
• What they did: A high-throughput screen of 5200 bioactive molecules identified dabrafenib as capable of restoring endothelial cell junctions and vascular barrier functions in CCM3-deficient cells, with further testing in acute and chronic mouse models.
• The result: Dabrafenib decreased cerebral lesion burden, suppressed lesion permeability, and rescued vascular defects, acting through ERK5-KLF2/4 signaling and F-actin stress fiber suppression, independently of BRAF pathway inhibition.